Business
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
WESTMINSTER, Colo., December 04, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and cu
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"WESTMINSTER, Colo., December 04, 2025--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and current treatment landscape for symptomatic thyroid disease. To register, click here.","length":620,"tagName":"p"},{"type":"text","content":"The event will provide an overview of the TriNav Infusion System and its Pressure-Enabled Delivery for Thyroid Artery Embolization (PED-TAE) approach. PED-TAE targets the inferior thyroid arteries and aims to reduce gland size and alleviate symptoms in patients who are not candidates for surgery or conventional therapies.","length":323,"tagName":"p"},{"type":"text","content":"A question and answer session will follow the formal presentations.","length":67,"tagName":"p"},{"type":"text","content":"About Juan C. Camacho, MD","length":25,"tagName":"p"},{"type":"text","content":"Juan C. Camacho, MD is an Interventional Radiologist and Clinical Associate Professor at Florida State University, specializing in image-guided thyroid therapies. He completed advanced training in interventional radiology at Emory University with subsequent faculty appointments moving then to lead academic medical centers like MUSC and Memorial Sloan Kettering. Dr. Camacho has authored more than 80 peer-reviewed publications and delivered numerous invited national and international lectures. His thyroid related research spans preclinical to clinical studies in minimally invasive thyroid interventions including thyroid ablation for malignancies, and he currently leads pioneering work in pressure-enabled thyroid artery embolization for benign thyroid disorders.","length":769,"tagName":"p"},{"type":"text","content":"About TriSalus Life Sciences","length":28,"tagName":"p"},{"type":"text","content":"TriSalus Life Sciences® is a growing, oncology focused medical technology business bringing disruptive drug delivery technology with the goal of improving therapeutic delivery for the treatment of both onc...